AstraZeneca’s Imfinzi-tarlatamab combination cuts death risk 58% in Phase III lung cancer trial

• AstraZeneca’s Imfinzi combined with Amgen’s tarlatamab-dlle improved survival versus Imfinzi alone in the Phase III DeLLphi-305 extensive-stage small cell lung cancer trial.
• The first-line maintenance treatment also delayed disease progression in patients whose cancer had not progressed following initial chemoimmunotherapy.
• Severe treatment-related adverse events were more common with the combination, which caused no treatment-related deaths.
• Results will be presented today at the ESMO Congress 2026 in Madrid; findings were also published in The New England Journal of Medicine.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AstraZeneca plc published the original content used to generate this news brief via Business Wire (Ref. ID: 202610241035BIZWIRE_USPR_____20261024_BW292075) on October 24, 2026, and is solely responsible for the information contained therein.